Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole‐Heart Model of Short QT Syndrome

Abstract

In the present pharmacologic model of short QT syndrome treatment with pinacidil led to an increased inducibility of VF in association with a reduction in ERP. Additional treatment with ranolazine or vernakalant reversed this effect and demonstrated potent antiarrhythmic properties based on an increase of ERP.